Transmembrane activator and CAML interactor (TACI) : another potential target for immunotherapy of multiple myeloma?
Multiple myeloma (MM) has emerged as the next most likely oncological or hematological disease indication amenable for cellular immunotherapy. Much of the attention has been focused on B cell maturation antigen (BCMA) as a unique cell surface protein on myeloma cells that is available for monoclonal...
Saved in:
| Main Authors: | , |
|---|---|
| 其他作者: | |
| 格式: | Article |
| 語言: | English |
| 出版: |
2021
|
| 主題: | |
| 在線閱讀: | https://hdl.handle.net/10356/145955 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|